GSK
GSK
779 hedge funds and large institutions have $10.8B invested in GSK in 2018 Q1 according to their latest regulatory filings, with 100 funds opening new positions, 291 increasing their positions, 250 reducing their positions, and 82 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 9 → 15 (+6)
22% more first-time investments, than exits
New positions opened: 100 | Existing positions closed: 82
16% more repeat investments, than reductions
Existing positions increased: 291 | Existing positions reduced: 250
11% more capital invested
Capital invested by funds: $9.69B → $10.8B (+$1.09B)
2% more funds holding
Funds holding: 764 → 779 (+15)
0.04% more ownership
Funds ownership: 4.41% → 4.45% (+0.04%)
21% less call options, than puts
Call options by funds: $133M | Put options by funds: $168M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCIM
Black Creek Investment Management
Toronto,
Ontario, Canada
|
+$228M |
| 2 |
Dodge & Cox
San Francisco,
California
|
+$166M |
| 3 |
EIC
Equity Investment Corp
Atlanta,
Georgia
|
+$40.9M |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$40.6M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$36.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$158M |
| 2 |
Two Sigma Advisers
New York
|
-$105M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$71.1M |
| 4 |
Renaissance Technologies
New York
|
-$58M |
| 5 |
Two Sigma Investments
New York
|
-$56.5M |
GSK Hedge Fund Activity: Q1 2018 in Review
779 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2018, worth a combined $10.8B — up 11% from $9.69B a quarter earlier.
Buyers outnumbered sellers: 100 funds opened new GSK positions and 82 closed out — a net gain of 18 holders — while 291 added to existing stakes and 250 trimmed.
The largest buyer was Black Creek Investment Management, opening a new position worth an estimated $228M. The largest seller was Royal Bank of Canada, cutting an estimated $158M.
- 779 institutional investors held GSK (GSK) as of Q1 2018, up from 764 in Q4 2017.
- Funds reported $10.8B of GSK stock for Q1 2018, up 11% quarter-over-quarter.
- 100 funds opened new GSK positions in Q1 2018 and 82 closed out, a net change of +18 holders.
- The largest GSK buyer in Q1 2018 was Black Creek Investment Management, an estimated $228M added.
- The largest GSK seller in Q1 2018 was Royal Bank of Canada, an estimated $158M sold.
Based on aggregated 13F filings for Q1 2018.